How much does Humira cost without insurance?
Humira (adalimumab), used for conditions like psoriasis, Crohn's disease, and rheumatoid arthritis, has a wholesale acquisition cost (WAC) of about $6,657 for a 2-pack of 40 mg/0.8 mL pens, or roughly $82 per mg.[1] Annual costs for maintenance dosing often exceed $80,000 before rebates or insurance.
Skyrizi pricing for the same conditions
Skyrizi (risankizumab-rzaa), approved for plaque psoriasis, psoriatic arthritis, and Crohn's disease, costs $5,685 per 150 mg/mL dose (two 75 mg prefilled syringes) at WAC, or about $38 per mg.[1] For psoriasis, the induction phase (four doses over 12 weeks) totals around $22,740, with maintenance at $11,370 every 12 weeks—annual costs near $50,000.
Why Skyrizi costs less than Humira per year
Skyrizi's dosing schedule (fewer injections) and lower per-mg price reduce total spend compared to Humira's weekly or biweekly use.[1] Real-world net prices after rebates drop further: Humira around $40,000-$50,000 annually, Skyrizi $20,000-$30,000, though exact rebates vary by payer and negotiation.[2]
With insurance or patient assistance—what patients actually pay
Copays average $50-$100 monthly for both with commercial insurance, but deductibles can hit $1,000+ early in the year.[3] AbbVie's myAbbVie Assist offers Humira copay cards capping out-of-pocket at $5/month for eligible patients; Skyrizi has similar programs via Skyrizi Complete, often $0 after enrollment.[4] Medicare Part D patients face higher hurdles post-2025 IRA changes.
Biosimilars driving down Humira prices now
Humira faces over 10 FDA-approved biosimilars (e.g., Hadlima, Yusimry) since 2023, with WAC prices 75-85% lower—$1,000-$2,000 per 2-pack.[1][5] This has forced Humira discounts, but brand uptake lingers due to inertia. Skyrizi, still patent-protected until at least 2033, lacks biosimilars.[6]
How do costs compare head-to-head by condition?
| Condition | Humira Annual WAC | Skyrizi Annual WAC | Notes |
|--------------------|-------------------|--------------------|-------|
| Plaque Psoriasis | ~$80,000 | ~$47,000 | Skyrizi every 12 weeks vs. Humira weekly[1] |
| Psoriatic Arthritis | ~$80,000 | ~$47,000 | Similar dosing edge for Skyrizi[1] |
| Crohn's Disease | ~$80,000 | ~$60,000 (induction heavy) | Skyrizi newer approval[7] |
Net prices after PBM rebates make Skyrizi cheaper in most formularies.[2]
[1]: DrugPatentWatch.com
[2]: IQVIA National Prescription Audit, 2024
[3]: GoodRx pricing data, Oct 2024
[4]: AbbVie patient assistance sites
[5]: FDA biosimilar approvals list
[6]: DrugPatentWatch.com
[7]: Skyrizi PI and Humira PI